Fosun Pharma (02196.HK), a subsidiary of Fosun Pharmaceutical, plans to invest a total of 1.412 billion yuan to acquire a controlling stake in Green Valley Pharmaceuticals.

Intelligence Financial APP News, Fosun Pharma (02196.HK) announced that in order to focus on unsatisfied clinical needs, further enrich the innovation product pipeline matrix in the central nervous system treatment field of the group, improve market layout, and create integrated diagnosis and treatment, multi-technology collaborative solutions, its subsidiary Fosun Pharma Industry intends to invest a total of 1,412.481633 million yuan to acquire a controlling stake in Green Valley Pharmaceuticals, including: